NCT02230579View on ClinicalTrials.gov

Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Malaria
Interventions
DRUG

MMV390048 5mg

"Supplied as powder in bottle formulation for reconstitution pre-dose"

DRUG

MMV390048 20mg

"Supplied as powder in bottle formulation for reconstitution pre-dose."

DRUG

MMV390048 40mg

"Supplied as powder in bottle formulation for reconstitution pre-dose"

DRUG

MMV390048 80mg

"Supplied as powder in bottle formulation for reconstitution pre-dose"

DRUG

MMV390048 120mg

"Supplied as powder in bottle formulation for reconstitution pre-dose"

DRUG

Placebo to match MMV390048

"Supplied as powder in bottle formulation for reconstitution pre-dose"

Trial Locations (1)

Unknown

Cinical Pharmacology, University of Cape Town, Cape Town

All Listed Sponsors
collaborator

University of Cape Town

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT02230579 - Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter